Explore Health Resources Learn where our story began, and how we continue to evolve alongside our customers
Sobo patients, the safest interpretation is this: Retatrutide may represent an important future direction in metabolic medicine, but any GLP-1, peptide, or weight-loss therapy should be evaluated through a medically supervised plan not self-directed online purchasing
Projections show continued explosive growth: From 2025 to 2030, Ozempic, Rybelsus, Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) are forecasted to generate $400 billion in additional U.S
Preguntas frecuentes sobre el GLP-1, respondidas por expertos en prdida de peso de U of U Health Preguntas frecuentes sobre el GLP-1, respondidas por expertos en prdida de peso de U of U Health No faltan noticias sobre los medicamentos con GLP-1
The oral formulation of semaglutide (now marketed as oral Wegovy following FDA approval in December 2025 and US launch in early 2026) carries its own separate patent protection, expected to extend until 2030 or beyond
And with weight loss, consistency is often what turns a promising start into real progress
